De novo protein decoys block COVID-19 infection in vitro and protect animals in vivo

Neoleukin Therapeutics, Inc., «Neoleukin» (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2. This report details the creation of de novo protein decoys that were specifically…

Details

Llama nanobodies could be a powerful weapon against COVID-19

PITTSBURGH, Nov. 5, 2020 — Today in Science, researchers at the University of Pittsburgh School of Medicine describe a new method to extract tiny but extremely powerful SARS-CoV-2 antibody fragments from llamas, which could be fashioned into inhalable therapeutics with the potential to prevent and treat COVID-19. These special llama antibodies, called «nanobodies,» are much…

Details

Nanobodies that neutralize SARS-CoV-2

Two separate studies have identified nanobodies — which could be produced less expensively than monoclonal antibodies — that bind tightly to the SARS-CoV-2 spike protein and efficiently neutralize SARS-CoV-2 in cells. «The combined stability, potency, and diverse epitope engagement of our … nanobodies … provide a unique potential prophylactic and therapeutic strategy to limit the…

Details

Keeping our cool

Fossil fuel burning accounts for the majority of global greenhouse gas emissions, and to the world’s credit, several countries are working to reduce their use and the heat-trapping emissions that ensue. The goal is to keep global temperatures under a 1.5° to 2°C increase above preindustrial levels — the upper limits of the Paris Climate…

Details

Children produce different antibodies in response to SARS-CoV-2

NEW YORK, NY (Nov. 5, 2020)—Children and adults produce different types and amounts of antibodies in response to infection with the new coronavirus, SARS-CoV-2, a new study from researchers at Columbia University Vagelos College of Physicians and Surgeons has found. The differences in antibodies suggest the course of the infection and immune response is distinct…

Details

Pediatric IBD Foundation, ImproveCareNow, C-Path establish CREATE safety registry

TUCSON, Ariz., November 5, 2020 — The Pediatric IBD Foundation, ImproveCareNow, and the Critical Path Institute (C-Path) are proud to announce a collaboration establishing the Children’s Registry for the Advancement of Therapeutics (CREATE™). CREATE™ is a drug-agnostic safety registry designed to support the completion of global post-marketing safety requirements, as well as collect safety information…

Details

Brain magnetic stimulation for veterans with concussion: Need is high, but evidence is limited

November 5, 2020 — Studies using repetitive transcranial magnetic stimulation (rTMS), a noninvasive technique, to help veterans and active-duty service members living with depression, post-traumatic stress disorder (PTSD), and other lasting consequences of concussion have shown promise. However, there’s an urgent need for studies designed to address the unique patterns of post-concussion symptoms seen in…

Details

Denmark Will Kill All Farmed Mink, Citing Covid Infections

The Danish government will slaughter millions of mink at more than 1,000 farms, citing concerns that a mutation in the novel coronavirus that has infected the mink could possibly interfere with the effectiveness of a vaccine for humans. Prime Minister Mette Frederiksen made the announcement at a news conference on Wednesday. There are 15 million…

Details

The View From Another Window

Welcome. Through the window where I work these days, I see the backs of several apartment buildings, terraces and fire escapes, tall old trees taken over by vines and the twin spires of the Gothic Revival-style church on the corner. As views go, it’s performing its job well: form and function in equal measure, beautiful…

Details